ICON
ICON plc is a global top-3 clinical research organization (CRO) that provides outsourced drug development services across the full clinical lifecycle to pharmaceutical, biotechnology, medical device, and government clients, operating in 47 countries with 38,000 employees and ~$8.25B in annual revenue.
- Company typePublic
- Founded1990
- HeadquartersDublin, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ICON does
ICON plc is a global clinical research organization (CRO) founded in 1990 and headquartered in Dublin, Ireland, listed on NASDAQ under the ticker ICLR. The company provides outsourced drug development services to pharmaceutical, biotechnology, medical device, biosimilar, generic, and government/public health organizations across the full clinical lifecycle, including early phase research, clinical operations, laboratory services, medical imaging, cardiac safety, pharmacovigilance, regulatory affairs, decentralized trials, and real-world evidence. Following the 2021 acquisition of PRA Health Sciences for approximately $12B, ICON operates with 38,000 employees across 47 countries, generating $8.25B in FY2025 revenue, and maintains the Accellacare site network providing access to 6.3M+ patients across 50+ sites in 4 countries.
ICON generates revenue primarily through fee-for-service contracts negotiated per clinical trial or program, with multi-year engagement structures including full-service outsourcing and Functional Services Provision (FSP) arrangements. Its GTM motion is concentrated enterprise field sales targeting large pharma and mid-to-large biotech sponsors, with over 40% of revenue derived from its top 10 customers. The company has built a proprietary technology stack centered on the Orbis multi-agent AI platform, the FIRECREST site management platform, the Language Services Portal (300+ languages), and a recently announced three-year enterprise-wide AI deployment with Microsoft (Microsoft 365 Copilot, Azure, Microsoft Fabric). Complementary proprietary tools include iSubmit, SmartDraft, EngageAI, and Cassandra, alongside the Advarra-integrated connected site network and the Symphony Health commercial data business (currently being divested to HealthVerity). Recent strategic emphasis has been on AI-driven operational efficiency, early phase capacity expansion (notably a new 69,500 sq ft San Antonio Clinical Research Unit in May 2026), and emerging therapeutic verticals such as obesity and cell and gene therapy.
ICON firmographics
Firmographics- Name
- ICON
- Legal name
- ICON plc
- Website
- https://iconplc.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ICON plc is a global top-3 clinical research organization (CRO) that provides outsourced drug development services across the full clinical lifecycle to pharmaceutical, biotechnology, medical device, and government clients, operating in 47 countries with 38,000 employees and ~$8.25B in annual revenue.
- Ownership category
- akta.pro rank
ICON industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Professional, Scientific, and Technical Services (541)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Functional Service Providers (FSP) & Resourcing CROs (HLAGAAAM), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)
Keywords
Where ICON is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices10 records
Markets served
ICON business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Revenue model
- Clinical Research Services: ICON generates revenue by providing outsourced clinical trial services across the drug development lifecycle, including early phase research, clinical operations, laboratory services, medical imaging, cardiac safety, pharmacovigilance, regulatory affairs, and real-world evidence solutions. Revenue is earned through service fees under contracts with pharmaceutical, biotechnology, government, and medical device companies. Late-stage trials in oncology, CNS disorders, and rare diseases represent key growth areas. The company also earns revenue from functional services provision (FSP) arrangements and full-service outsourcing engagements.
- Specialized Early Phase Services: Revenue from dedicated Phase I clinical research units supporting first-in-human and patient cohort studies, including clinical pharmacology, bioanalytical laboratory services, and GMP/GCP-compliant pharmacy services.
- Site and Patient Solutions: Revenue from the Accellacare site network and patient recruitment services, providing faster site initiation (58% faster to site initiation visit than non-Accellacare sites) and improved patient access for sponsors.
- Regulatory Affairs Services: Revenue from regulatory affairs consulting services, including December 2025 acquisition of a regulatory tech startup that reportedly reduced approval timelines by 30% for complex cell and gene therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CRO service contracts negotiated per clinical trial or program. |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
ICON product offering
Product offeringCore offering
ICON plc is a global Contract Research Organization (CRO) that provides outsourced drug development services to pharmaceutical, biotechnology, medical device, biosimilar and generic organizations. The company delivers full-service clinical research, functional service provision (FSP), laboratory, medical imaging, cardiac safety, decentralized trial, regulatory, real-world evidence, and site/patient solutions across all phases of drug development in 47 countries.
Differentiator
Problem solved
Functional benefit
Brands
- Orbis: ICON's multi-agent AI platform that connects human expertise, data and AI across the clinical trial lifecycle
- Accellacare Site Network
- Symphony Health
- FIRECREST
Products and services
- Clinical & Scientific Operations
- Early Clinical / Phase I Services
- Accellacare Site Network
- Orbis AI Platform
- Cardiac Safety Solutions
- Medical Imaging Services
- Laboratory Services
- Decentralised Clinical Trials
- Regulatory Affairs Services
- Real World Solutions
- Language Services
- Asset Development Consulting
- Commercial Positioning Consulting
- Outcome Measures
- Symphony Health Data Solutions
- Center for Obesity Dedicated clinical trial center with 100+ U.S. sites focused on obesity drug development, providing site network, patient recruitment, and protocol design for obesity therapies.
Quantifiable outcome
- 58% faster to site initiation visit compared to non-Accellacare sites
- +4 more outcomes
Companies that use ICON
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
ICON technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability9 records
Feature8 records
ICON partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and strategic.
- MicrosoftcoreICON selected Microsoft as its preferred technology partner for a three-year digital innovation and AI investment plan. The partnership involves enterprise-wide deployment of Microsoft 365 Copilot and Microsoft Azure cloud infrastructure, including Microsoft Fabric and Azure data services, to scale ICON's Orbis agentic AI platform across clinical, operational, and enterprise data. The collaboration aims to accelerate study design, streamline operational execution, enhance patient and site engagement, and strengthen real-time decision-making throughout the clinical trial lifecycle. CEO Barry Balfe stated the company is determined to be at the forefront of AI adoption in clinical trials.
- Banyan BioInnovationsstrategicBanyan BioInnovations, an offshoot of Boston-based life science investment bank Locust Walk, partnered with ICON to improve trial execution, design, and commercialization strategy for its clinical-stage companies ('NewCos'). Banyan launched with over $100 million in funding and 50 team members. The partnership enables Banyan's portfolio companies to leverage ICON's comprehensive CRO services across clinical development programs.
- HealthVeritystrategicHealthVerity announced the acquisition of Symphony Health Solutions Corporation, a commercial healthcare data and analytics business that was previously part of ICON plc (acquired through ICON's 2021 purchase of PRA Health Sciences). Symphony Health provides data aggregation, consulting services, and commercial strategy tools. The transaction is expected to close in May 2026, transferring ICON's Symphony Health subsidiary to HealthVerity.
- AdvarracoreICON and Advarra entered into a definitive partnership to introduce a new 'research-ready,' connected site network model for clinical trials, integrating ICON's global clinical trial solutions with Advarra's site CTMS, eISF, and eSource systems used by more than 50,000 investigators worldwide. The initiative aims to reduce administrative friction, accelerate study startup, increase clinical trial participation, and equip emerging and research-naïve sites with standardized technology. Advarra's Braid data and AI platform will supply ICON with operational intelligence to improve protocol design, planning, and site selection.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
ICON competitors and assessment
Company assessmentDirect peers
- IQVIA Holdings: IQVIA is the largest global CRO and ICON's primary direct competitor, offering similar end-to-end clinical research, technology, and real-world evidence services to pharma, biotech, and medical device sponsors. Both companies compete head-to-head on full-service outsourcing, FSP, and late-stage clinical trial programs for large pharma clients.
- Labcorp (Covance Clinical Services): Labcorp's Covance division is a top-tier global CRO with broad clinical and laboratory service offerings spanning early through late-stage development. Directly comparable to ICON in scale, end-to-end service model, and target customer base of large pharma and biotech sponsors.
- Charles River Laboratories: Charles River is a major CRO with particular strength in early-stage and preclinical research, discovery, and safety assessment. While it overlaps more on the early-phase and laboratory side, it competes directly with ICON's early clinical, bioanalytical, and research services.
- Medpace Holdings: Medpace is a mid-sized full-service CRO with a strong reputation in oncology, metabolic, and cardiovascular trials, known for organic growth and superior margins. Directly comparable to ICON in therapeutic focus and full-service clinical trial execution, though smaller in scale.
- Parexel International: Parexel is a global full-service CRO (taken private by EQT and Goldman Sachs Asset Management in 2021) competing head-to-head with ICON across Phase I-IV clinical trials, biostatistics, and regulatory services. Highly comparable in scale, service breadth, and customer mix.
- Syneos Health: Syneos Health is a top-tier CRO offering clinical and commercial services to pharma and biotech, recently taken private by Elliott Investment Management. Directly comparable to ICON as a full-service clinical research and commercialization services provider.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO specializing in neuroscience, oncology, cardiometabolic, and rare disease trials. Direct peer to ICON in therapeutic focus areas and mid-size clinical trial outsourcing.
- Fortrea Holdings: Fortrea was spun off from Labcorp in 2023 as an independent CRO focused on clinical development and commercialization services. Directly comparable to ICON in late-stage clinical trial services and post-approval/real-world evidence work.
Broad incumbents
- Thermo Fisher Scientific (PPD): Thermo Fisher acquired PPD in 2021 for $17.4B, adding a major global CRO to its broader life sciences tools and services portfolio. Competes with ICON as part of a diversified life sciences platform rather than a pure-play CRO, but offers overlapping clinical development services.
Regional players
- WuXi AppTec: WuXi AppTec is a leading China-based CRO/CDMO offering clinical and preclinical services globally. Direct service overlap with ICON in clinical operations and laboratory services, though primarily serving Asia-based biotech sponsors and facing US BIOSECURE-related headwinds.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
ICON social profiles
Digital presenceICON financial estimates
Financial estimateRevenue estimate
Valuation estimate
ICON leadership team
Management profileNumber of profiles
Profiles11 records
ICON subsidiaries and ownership
Company hierarchySubsidiaries2 records
ICON funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ICON M&A and investment
M&A and investmentM&A21 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ICON
What does ICON do?
ICON plc is a global Contract Research Organization (CRO) that provides outsourced drug development services to pharmaceutical, biotechnology, medical device, biosimilar and generic organizations. The company delivers full-service clinical research, functional service provision (FSP), laboratory, medical imaging, cardiac safety, decentralized trial, regulatory, real-world evidence, and site/patient solutions across all phases of drug development in 47 countries.
Is ICON a public or private company?
ICON is a public company. It is classified as public and is currently operating.
When was ICON founded?
ICON was founded in 1990. It employs 1 to 10 people.
Where is ICON based?
ICON is headquartered in Dublin, Ireland, in the Europe region.
How does ICON make money?
Four revenue lines are on record. Clinical Research Services are the primary driver. The others are specialized Early Phase Services, site and Patient Solutions and regulatory Affairs Services.
Who are ICON's main competitors?
Direct peers on record are IQVIA Holdings, Labcorp (Covance Clinical Services), Charles River Laboratories, Medpace Holdings, Parexel International, Syneos Health, Worldwide Clinical Trials and Fortrea Holdings. Thermo Fisher Scientific (PPD) is listed as a broad incumbent. WuXi AppTec is listed as a regional player.
Does ICON have an API?
No public API is recorded for ICON.
What industry is ICON in?
ICON's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417.